Core Insights - CalciMedica's Auxora has shown significant potential in reducing IL-17-related inflammation and improving kidney function in a rat model of acute kidney injury (AKI) [1][3][6] - The company is currently evaluating Auxora in the Phase 2 KOURAGE trial for severe AKI with respiratory failure, reinforcing its therapeutic potential [1][4] Study Findings - In a study involving rat models of ischemia/reperfusion-induced AKI, Auxora (16 mg/kg) was administered intravenously, leading to a significant increase in glomerular filtration rate (GFR) and a reduction in renal injury [2][6] - Three-day dosing of Auxora resulted in a 64% reduction in Th-17 cells in the kidney and a 59% reduction in the lung, along with a 69% decrease in IL-6-producing CD4 cells [6] Mechanistic Support - The study provided strong mechanistic support for Auxora as a treatment for severe AKI with acute hypoxemic respiratory failure (AHRF), highlighting the correlation between elevated IL-17 levels and adverse kidney events [3][4] - Down-regulation of IL-17 may be crucial in mitigating multi-organ failure, which is common in critically ill patients with severe AKI [3] Company Overview - CalciMedica is a clinical-stage biopharmaceutical company focused on developing CRAC channel inhibition therapies for inflammatory and immunologic diseases, with a proprietary technology aimed at modulating immune responses [5][7] - The company has conducted multiple efficacy clinical trials for Auxora, which has been well-tolerated in over 350 critically ill patients [7]
CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025